Neutrolin®是一种抗凝血剂和广谱抗菌，由Cormedix/Cormedix GmbH公司开发作为一种预防性溶液以降低感染和血液凝块（血栓）的威胁的非抗生素类抗感染的新药。
NEUTROLIN Katheter-Lock-Lösung Durchstechflaschen
Cormedix Europe GmbH
Packung:10X5.8 Milliliter
包装：5.8ml*10/盒
Neutrolin®封管液，用于患者的血液透析继发于晚期慢性肾脏病中心静脉导管。该解决方案包括抗凝血剂和广谱抗菌（抗菌和抗真菌）组合所做的是对常见的微生物包括抗生素耐药株的活性Neutrolin，另外，抑制生物膜的形成。
Neutrolin® 作为封管溶液，已被证明是显着降低导管相关血流感染（CRBIs）的发生率，以及通过抑制血栓形成保持导管通畅，从而减少了全身性抗生素的需要，并延长中心静脉导管寿命。
Neutrolin® Catheter Lock Solution
Neutrolin    Overview
Clinical TrialsNeutrolin® is a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping central venous catheters (CVCs) operating safely and efficiently.  Neutrolin is approved as a CE Marked medical device in Europe where, in post-market studies, it was shown to reduce catheter-related bloodstream infections by 96% and thrombosis by 96.7% compared to historical benchmarks.  In the United States, where Neutrolin is not yet approved, the product is regulated as a drug and is in Phase 3 clinical development.
Neutrolin is a proprietary formulation of taurolidine 1.35%, citrate 3.5% and heparin 1000 units/mL that is used to fill catheter lumens when they are not in use, keeping them sterile and preventing blood clots (thrombosis).  Taurolidine, the key compound in Neutrolin, is an amino acid derivative with broad antimicrobial activity against gram-positive and gram-negative bacteria, including antibiotic resistant strains, as well as mycobacteria and clinically relevant fungi including Aspergillus.
Neutrolin may ultimately benefit adult and pediatric patients with long-term CVCs and peripherally inserted central catheters (“PICCs”). These patients include: those undergoing hemodialysis (a form of dialysis where the patient’s blood is circulated through a dialysis filter), receiving chemotherapy and basic fluids, long term antibiotic therapy, parenteral nutrition (complete or partial dietary support via intravenous nutrients) and those receiving acute treatment in the intensive/critical care unit.
A post-market clinical utility study eva luated the use of Neutrolin in the prevention of catheter-related blood infections (CRBSIs) and thrombosis.
Under the study, 202 hemodialysis patients at 20 hemodialysis centers in Germany were enrolled in the ongoing Neutrolin Use Monitoring Program (NUMP), representing 15,464 dialysis sessions over a 26-month period, for a total of 36,083 hemodialysis catheter days.
These data demonstrated that use of Neutrolin is associated with 96.0% reduction in the rate of CRBSI and 96.7% reduction in thrombosis compared to published historical benchmarks of 3.5 CRBSIs and 2-3 episodes of thrombosis per 1,000 catheter days. No significant adverse drug reactions that led to the discontinuation of Neutrolin use were reported. Real world data from the Neutrolin Use Monitoring Program also indicated that Neutrolin:
•Helps prevent inflammatory complications, which are a primary cause of morbidity among end-stage renal disease hemodialysis patients
•Reduces the need for local and systemic antibiotics, which can increase microbial resistance and infection risks
•Reduces the likelihood of catheter failures
•Prolongs catheter life, thus reducing the need for reinsertion procedures
•Reduces hospital lengths of stays
Target Market
Every day with a CVC presents a risk for an infection to develop.  There are 250,000 CRBSIs in the U.S. per year, which are also referred to as central line-associated bloodstream infections (CLABSI). 
Along with thrombosis, these key complications can lead to treatment delays and increased costs to the healthcare system, and higher mortality rates.